reports
- Stijn Demeester
Fagron/Expect a softer 1Q26, reiteration of FY guidance/BUY
We update our estimates with our c.6% higher Adj. EBITDA estimates for 2026F-28F largely driven by recent M&A's. We expect Fagron's trading update on 9 April to point to a somewhat softer quarter, reflecting temporary headwinds in the North American compounding segment. However, Fagron should reiterate its FY26 guidance of mid- to high-single digit organic revenue growth as growth should spring back in 2H26 as GLP1 headwinds fade. We reiterate our BUY recommendation and €27 per share target pric...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update April 2026: Adding Fagron
The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
FAGR FAGRON SA
WKL WOLTERS KLUWER NV
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
- Francesca Ferragina
- Michiel Vereycken
WHA WERELDHAVE N.V.
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
RET RETAIL ESTATES NV
VASTB VASTNED RETAIL BELGIUM NV
MONT MONTEA SCA
AED AEDIFICA SA
ASC ASCENCIO SCA
VGP VGP NV
NSI NSI N.V.
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
19XX NEPI ROCKCASTLE N.V.
- ING Helpdesk
- Francesca Ferragina
- Michiel Vereycken
Retail Real Estate Update/Looking for defensiveness
The retail segment outperformed in 2025 driven by strong operational momentum. Fundamentals remain strong but the Middle East conflict is a risk due to its impact on inflation/rates, energy prices and purchasing power. That is why we favour defensive names: we reward food exposure, convenience centres and low OCRs mixed with healthy balance sheets. Retail Estates ticks all the boxes. Eurocommercial has the cheapest valuation (41.5% discount to 2026F NAV) and its dominant shopping centres have de...
Fagron increases share capital through exercise subscription rights
Fagron increases share capital through exercise subscription rights Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84. The total number of shares with voting rights after the issue amounts to 73,773,104 which is also ...
Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten
Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 31 maart 2026 – 19:00u. CET Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Fagron maakt bekend dat er op 31 maart 2026 104.200 nieuwe aandelen zijn uitgegeven als gevolg van de uitoefening van inschrijvingsrechten. Overeenkomstig de Belgische transparantiewetgeving deelt Fagron mee dat haar maatschappelijk kapitaal na de uitgifte € 507.462.601,84 bedraagt. Het totaal aantal stemrechtverlenende effecten na de uitgifte bedraagt 73.773.1...
- Jacob Mekhael
UCB Kygevvi receives EC approval in ultra-rare disease TK2d
UCB announced that the European Commission approved Kygevvi (doxecitine and doxribtimine) under exceptional circumstances as the first and only treatment for paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. The approval comes after the positive CHMP opinion announced in February 2026. Beyond the EU, the product received FDA approval in the US in 4Q25. € 284 TP and BUY maintained.
- Jacob Mekhael
Inventiva FY25 results narrow lani phase 3 MASH readout timing to 4Q26
Inventiva's FY25 results come with narrowed timeline guidance for the topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which is expected in 4Q26 (previously 2H26). We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the MASH commercial opportunity. Inventiva confirmed its cash runway guidance to middle of 1Q27, beyond the key milestone...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Lewi
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 31, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
Inventiva reports 2025 full year results and provides a business updat...
Inventiva reports 2025 full year results and provides a business update Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase 3 clinical tr...
Inventiva publie ses résultats financiers annuels 2025 et fait le poi...
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme1 au 31 décembre 2025Réalisation d'une offre au public aux États-Unis pour un produit brut d'environ 172,5 millions de dollars (149 millions d'euros2)Horizon de trésorerie prévu jusqu’au milieu du premier trimestre 20273Finalisation de la cession d'odiparcil avec des paiements d’étapes potentiels pouvant atteindre 90 millions de dol...
- Bruno Cavalier
- Luis de Toledo Heras
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
UTDI UNITED INTERNET AG
EL ESSILORLUXOTTICA SA
PHA PHARMAGEST INTERACTIVE SA
FAGR FAGRON SA
BRBY BURBERRY GROUP PLC
KER KERING SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
01913 PRADA S.P.A.
AIXA AIXTRON SE
MLP MLP SE
PAT PATRIZIA AG
MONC MONCLER SPA
ENG ENAGAS SA
SMHN SUESS MICROTEC AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TCH TECHNICOLOR SA
ZGN ERMENEGILDO ZEGNA NV
CTPNV CTP NV
DIA DISTRIBUIDORA INTERNACIONAL DE ALIMENTACION SA
- Bruno Cavalier
- Luis de Toledo Heras
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
UTDI UNITED INTERNET AG
EL ESSILORLUXOTTICA SA
PHA PHARMAGEST INTERACTIVE SA
FAGR FAGRON SA
BRBY BURBERRY GROUP PLC
VETO VETOQUINOL SA
KER KERING SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
01913 PRADA S.P.A.
AIXA AIXTRON SE
MLP MLP SE
PAT PATRIZIA AG
MONC MONCLER SPA
ENG ENAGAS SA
SMHN SUESS MICROTEC AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TCH TECHNICOLOR SA
ZGN ERMENEGILDO ZEGNA NV
DIA DISTRIBUIDORA INTERNACIONAL DE ALIMENTACION SA
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Robert Jan Vos
- Usama Tariq
- Jacob Mekhael
UCB New Bimzelx data in HS and PsO at AAD 2026
UCB presented updated data for Bimzelx in hidradenitis suppurativa (HS) and psoriasis (PsO) at the AAD conference, held 27–31 March. In HS, data showing better outcomes in patients with lower disease duration and severity makes the case for earlier treatment with Bimzelx, further supporting the drug's continued commercial uptake. In PsO, we're encouraged to see high rates of complete skin clearance up to 4 years in patients that stopped and re-started treatment, which should help UCB capture re-...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- David Vagman
- CFA
- Maxime Stranart
UCB/EmBOLDened by Bimzelx/BUY
We reiterate our BUY rating but cut our target price from €310 to €306, reflecting an increased equity risk premium due to the war in Iran. We continue to view UCB as a unique growth story in the industry, as we model core EPS to grow at c.30% CAGR over 2024-30F thanks to the continued growth of key blockbusters Bimzelx and Evenity. Next to these, we remain confident in UCB's long-term growth strategy with assets like Galvokimig, which continues to show efficacy data optically superior to other ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.